Table 3.
The meta-analysis of association between SII and clinicopathological factors in patients with RCC.
| Variables | No. of studies | No. of patients | Effects model | OR (95%CI) | p | Heterogeneity I 2(%) Ph | |
|---|---|---|---|---|---|---|---|
| Sex (male vs female) | 3 | 1,001 | Fixed | 1.51(1.11-2.04) | 0.008 | 42.8 | 0.174 |
| Histological type (non-clear cell vs clear cell) | 3 | 1,138 | Fixed | 1.04(0.72-1.51) | 0.840 | 4.7 | 0.350 |
| Fuhrman grade (G3-G4 vs G1-G2) | 2 | 833 | Random | 1.80(1.08-3.00) | 0.024 | 52.9 | 0.145 |
| T stage (T3-T4 vs T1-T2) | 2 | 833 | Random | 1.76(0.62-5.01) | 0.292 | 86.6 | 0.006 |
| Sarcomatoid differentiation (present vs absent) | 2 | 833 | Random | 1.74(0.50-6.06) | 0.382 | 58.9 | 0.119 |
| IMDC risk (poor vs favorable/intermediate) | 2 | 492 | Fixed | 19.12(9.13-40.06) | <0.001 | 0 | 0.698 |
IMDC, International Metastatic Renal Cell Carcinoma Database Consortium.